Business Description
Metropolis Healthcare Ltd
SIC : 8071
ISIN : INE112L01020
Total Employee Number:
5,180Compare
Compare
Traded in other countries / regions
542650.India Index Membership
NIFTY 500 IPO Date
2019-04-15Description
Metropolis Healthcare Ltd is an Indian diagnostics company that operates a network of clinical laboratories and collection centres across India, with a presence in select international markets including Africa and the Middle East. It provides a broad range of pathology and radiology tests, including routine blood work, specialised assays, molecular diagnostics, histopathology, and genetic testing, used for screening, diagnosis, and monitoring of disease. The company serves individual patients, hospitals, nursing homes, and corporate clients, and also offers laboratory and analytical support to clinical research organisations. Pathology services constitute its principal and only reportable business segment, generating revenue primarily through fee-for-service diagnostic testing billed to patients, healthcare providers, and institutional customers. Metropolis also operates through a mix of owned labs and franchisee-run collection networks, and has expanded via acquisitions of regional diagnostic chains.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.88 | |||||
Equity-to-Asset | 0.71 | |||||
Debt-to-Equity | 0.15 | |||||
Debt-to-EBITDA | 0.53 | |||||
Interest Coverage | 11.24 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 14.02 | |||||
Beneish M-Score | -2.7 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 12.5 | |||||
3-Year EBITDA Growth Rate | 11 | |||||
3-Year EPS without NRI Growth Rate | 13.5 | |||||
3-Year FCF Growth Rate | 15.2 | |||||
3-Year Book Growth Rate | 14.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 29.41 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 14.57 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 58.45 | |||||
9-Day RSI | 57.25 | |||||
14-Day RSI | 56.44 | |||||
3-1 Month Momentum % | 1.74 | |||||
6-1 Month Momentum % | 18.2 | |||||
12-1 Month Momentum % | 7.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.4 | |||||
Quick Ratio | 1.27 | |||||
Cash Ratio | 0.61 | |||||
Days Inventory | 46.5 | |||||
Days Sales Outstanding | 35.17 | |||||
Days Payable | 129.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.33 | |||||
Dividend Payout Ratio | 0.2 | |||||
3-Year Dividend Growth Rate | -20.6 | |||||
Forward Dividend Yield % | 0.33 | |||||
5-Year Yield-on-Cost % | 0.33 | |||||
3-Year Average Share Buyback Ratio | -0.4 | |||||
Shareholder Yield % | 0.18 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 79.17 | |||||
Operating Margin % | 16.78 | |||||
Net Margin % | 11.79 | |||||
EBITDA Margin % | 25.52 | |||||
FCF Margin % | 17.49 | |||||
OCF Margin % | 20.48 | |||||
ROE % | 14.14 | |||||
ROA % | 10.08 | |||||
ROIC % | 11.9 | |||||
3-Year ROIIC % | 11.99 | |||||
ROC (Joel Greenblatt) % | 73.01 | |||||
ROCE % | 17.83 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 61.58 | |||||
Forward PE Ratio | 50.21 | |||||
PE Ratio without NRI | 59.62 | |||||
Shiller PE Ratio | 67.44 | |||||
Price-to-Owner-Earnings | 53.32 | |||||
PEG Ratio | 19.23 | |||||
PS Ratio | 7.27 | |||||
PB Ratio | 8.18 | |||||
Price-to-Tangible-Book | 38.21 | |||||
Price-to-Free-Cash-Flow | 41.27 | |||||
Price-to-Operating-Cash-Flow | 35.24 | |||||
EV-to-EBIT | 41.29 | |||||
EV-to-Forward-EBIT | 30.99 | |||||
EV-to-EBITDA | 28.49 | |||||
EV-to-Forward-EBITDA | 22.54 | |||||
EV-to-Revenue | 7.28 | |||||
EV-to-Forward-Revenue | 5.68 | |||||
EV-to-FCF | 40.72 | |||||
Price-to-GF-Value | 0.98 | |||||
Price-to-Projected-FCF | 3.2 | |||||
Price-to-DCF (Earnings Based) | 5.02 | |||||
Price-to-DCF (FCF Based) | 2.27 | |||||
Price-to-Graham-Number | 10.32 | |||||
Earnings Yield (Greenblatt) % | 2.42 | |||||
FCF Yield % | 2.41 | |||||
Forward Rate of Return (Yacktman) % | 4.94 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Metropolis Healthcare Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 17,099.977 | ||
| EPS (TTM) (₹) | 9.711 | ||
| Beta | 0.6155 | ||
| 3-Year Sharpe Ratio | 0.57 | ||
| 3-Year Sortino Ratio | 1.05 | ||
| Volatility % | 25.35 | ||
| 14-Day RSI | 56.44 | ||
| 14-Day ATR (₹) | 17.300806 | ||
| 20-Day SMA (₹) | 583.34 | ||
| 12-1 Month Momentum % | 7.84 | ||
| 52-Week Range (₹) | 412.25 - 609.05 | ||
| Shares Outstanding (Mil) | 207.45 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Metropolis Healthcare Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Metropolis Healthcare Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2027 | 2027-02-05 09:00 | In 137 days | ||
| Third quarter earnings results for 2027 | 2027-02-04 | In 135 days | ||
| Second quarter earnings conference call for 2027 | 2026-11-06 09:00 | In 46 days | ||
| Second quarter earnings results for 2027 | 2026-11-06 | In 45 days | ||
| Large format Investors & Analyst Meet | 2026-08-27 16:00 | 570.30 (+0.58%) | ||
| General meeting for 2026 | 2026-08-18 10:00 | 550.75 (+1.33%) | ||
| First quarter earnings conference call for 2027 | 2026-08-05 09:00 | 584.50 (-2.15%) | ||
| First quarter earnings results for 2027 | 2026-08-05 | 584.50 (-2.15%) | ||
| Annual report for 2026 | 2026-07-27 | 570.25 (+0.06%) | ||
| INR 1.000000 Cash Dividend | 2026-05-19 | 507.40 (-2.89%) |
Show
Entries
Metropolis Healthcare Ltd Frequently Asked Questions
What is Metropolis Healthcare Ltd(NSE:METROPOLIS)'s stock price today?
The current price of NSE:METROPOLIS is ₹593.40. The 52 week high of NSE:METROPOLIS is ₹609.05 and 52 week low is ₹412.25.
When is next earnings date of Metropolis Healthcare Ltd(NSE:METROPOLIS)?
The next earnings date of Metropolis Healthcare Ltd(NSE:METROPOLIS) is 2026-11-06 Est..
Does Metropolis Healthcare Ltd(NSE:METROPOLIS) pay dividends? If so, how much?
The Dividend Yield %  of Metropolis Healthcare Ltd(NSE:METROPOLIS) is 0.33% (As of Today), Highest Dividend Payout Ratio of Metropolis Healthcare Ltd(NSE:METROPOLIS) was 0.31. The lowest was 0.1. And the median was 0.21. The  Forward Dividend Yield % of Metropolis Healthcare Ltd(NSE:METROPOLIS) is 0.33%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers